Targeting Free Radicals in Oxidative Stress-Related Human Diseases

Trends in Pharmacological Sciences

Volumn 38, Issue 7, 2017, Pages 592-607

  Poprac, Patrik ^a   Jomova, Klaudia ^b   Simunkova, Miriama ^a   Kollar, Vojtech ^c   Rhodes, Christopher J ^d   Valko, Marian ^a  

^a SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^b The Philosopher University in Nitra Geoinformatics and Regional Development   (Slovakia)

^c School of Economics and Management in Public Administration in Bratislava Slovak Republic   (Slovakia)

^d Fresh lands Environmental Actions   (United Kingdom)

Author keywords

Alzheimer's disease; antioxidants; cancer; oxidative stress; ROS

Indexed keywords

7 METHOXYTACRINE; ANTIOXIDANT; COPPER; DNA; FREE RADICAL; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TACRINE; THIOREDOXIN; ZINC; CHELATING AGENT; SCAVENGER;

ALZHEIMER DISEASE; ANTIOXIDANT ASSAY; CANCER INCIDENCE; CANCER PREVENTION; CHELATION; DEPLETION; GLUCOSE METABOLISM; HUMAN; MALIGNANT NEOPLASM; METABOLIC DISORDER; MODULATION; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; UPREGULATION; DRUG EFFECTS; METABOLISM; NEOPLASMS; PHYSIOLOGY;

ALZHEIMER DISEASE; ANTIOXIDANTS; CHELATING AGENTS; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 85019584181     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.04.005     Document Type: Review

References (96)

1. Behrens, M.I., et al. A common biological mechanism in cancer and Alzheimer's disease?. Curr. Alzheimer Res. 6 (2009), 196–204.
2. Driver, J.A., et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ, 344, 2012, e1442.
3. Plun-Favreau, H., et al. Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet. 6 (2010), 1–8.
4. Firuzi, O., et al. Antioxidant therapy: current status and future prospects. Curr. Med. Chem. 18 (2011), 3871–3888.
5. Valko, M., et al. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39 (2007), 44–84.
6. Wu, P., et al. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 36 (2015), 422–439.
7. Halliwell, B., Free radicals and antioxidants – Quo vadis?. Trends Pharmacol. Sci. 32 (2011), 125–130.
8. Lehoux, S., Redox signalling in vascular responses to shear and stretch. Cardiovasc. Res. 71 (2006), 269–279.
9. Gorrini, C., et al. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12 (2013), 931–947.
10. Weinstein, I.B., Joe, A., Oncogene addiction. Cancer Res. 68 (2008), 3077–3080.
11. Trachootham, D., et al. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 8 (2009), 579–591.
12. Jones, R.G., Thompson, C.B., Tumor suppressors and cell metabolism: a recipe for cancer growth Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 8 (2009), 537–548.
13. Halliwell, B., Oxidative stress and cancer: have we moved forward?. Biochem. J. 401 (2007), 1–11.
14. Blot, W.J., et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. 85 (1993), 1483–1492.
15. Zhang, W., et al. Vitamin intake and liver cancer risk: a report from two cohort studies in China. J. Natl. Cancer Inst. 104 (2012), 1173–1181.
16. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330 (1994), 1029–1035.
17. Klein, E.A., et al. Vitamin E and the risk of prostate cancer. JAMA 306 (2011), 1549–1556.
18. Carr, A., Frei, B., Does vitamin C act as a pro-oxidant under physiological conditions?. FASEB J. 13 (1999), 1007–1024.
19. Bast, A., Haenen, G.R.M.M., Ten misconceptions about antioxidants. Trends Pharmacol. Sci. 34 (2013), 430–436.
20. Richelle, M., et al. Skin bioavailability of dietary vitamin E, carotenoids, polyphenols, vitamin C, zinc and selenium. Br. J. Nutr. 96 (2006), 227–238.
21. Halliwell, B., Vitamin C: antioxidant or prooxidant in vivo?. Free Radic. Res. 25 (1996), 439–454.
22. Halliwell, B., Gutteridge, J.M.C., Free Radicals in Biology and Medicine. 4th edn, 2007, Oxford University Press.
23. Lambeth, J.D., Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic. Biol. Med. 43 (2007), 332–347.
24. Imlay, J.A., Cellular defenses against superoxide and hydrogen peroxide. Annu. Rev. Biochem. 77 (2008), 755–776.
25. Unger, F.T., et al. Prediction of individual response to anticancer therapy: historical and future perspectives. Cell. Mol. Life Sci. 72 (2015), 729–757.
26. Halliwell, B., Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies?. Arch. Biochem. Biophys. 476 (2008), 107–112.
27. Liou, G.-Y., Storz, P., Reactive oxygen species in cancer. Free Radic. Res. 44 (2010), 479–496.
28. Conklin, K.A., Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr. Cancer Ther. 3 (2004), 294–300.
29. Barrera, G., Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol., 2012, 2012, 137289.
30. Kummar, S., et al. Advances in using PARP inhibitors to treat cancer. BMC Med., 10, 2012, 25.
31. Kaufmann, S.H., Earnshaw, W.C., Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256 (2000), 42–49.
32. Zhang, Q., et al. Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells. Cancer Lett. 313 (2011), 201–210.
33. Hao, H., et al. HSP90 and its inhibitors. Oncol. Rep. 23 (2010), 223–230.
34. Neckers, L., Workman, P., Hsp90 molecular chaperone inhibitors: are we there yet?. Clin. Cancer Res. 18 (2012), 64–76.
35. Tai, D.-J., et al. Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Exp. Ther. Med. 4 (2012), 291–296.
36. Griffith, O.W., Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J. Biol. Chem. 257 (1982), 13704–13712.
37. − and thereby promotes tumor growth. Cancer Cell 19 (2011), 387–400.
38. Lo, M., et al. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr. Oncol. 17 (2010), 9–16.
39. Montero, A.J., et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer. Breast Cancer Res. Treat. 132 (2012), 215–223.
40. Fan, C., et al. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis., 5, 2014, e1191.
41. Kiebala, M., et al. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Exp. Hematol. 43 (2015), 89–99.
42. Marzano, C., et al. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 42 (2007), 872–881.
43. Wei, Q., et al. Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 19738–19743.
44. Wei, Q., et al. Sulfiredoxin–peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proc. Natl. Acad. Sci U. S. A. 108 (2011), 7004–7009.
45. Jiang, H., et al. Sulfiredoxin promotes colorectal cancer cell invasion and metastasis through a novel mechanism of enhancing EGFR signalling. Mol. Cancer Res. 13 (2015), 1554–1566.
46. Vaughn, A.E., Deshmukh, M., Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat. Cell Biol. 10 (2008), 1477–1483.
47. Simons, A.L., et al. Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J. Cancer Res. Ther. 5:Suppl. 1 (2009), S2–S6.
48. Patra, K.C., Hay, N., The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39 (2014), 347–354.
49. Polimeni, M., et al. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem. J. 439 (2011), 141–149.
50. Greenough, M.A., et al. Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem. Int. 62 (2013), 540–555.
51. Kell, D.B., Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch. Toxicol. 84 (2010), 825–889.
52. Butterfield, D.A., The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radic. Biol. Med. 74 (2014), 157–174.
53. Korabecny, J., et al. 7-methoxytacrine-p-anisidine hybrids as novel dual binding site acetylcholinesterase inhibitors for Alzheimer's disease treatment. Molecules 20 (2015), 22084–22101.
54. Birks, J., Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev., 2006, 2006, CD005593.
55. Persson, T., et al. Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail?. Oxid. Med. Cell. Longev., 2014, 2014, 427318.
56. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
57. Akundi, R.S., et al. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS One, 6, 2011, e16038.
58. Cole, S.L., Vassar, R., The role of amyloid precursor protein processing by BACE1, the β-secretase, in Alzheimer disease pathophysiology. J. Biol. Chem. 283 (2008), 29621–29625.
59. Gu, Z., et al. Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol. Neurobiol. 41 (2010), 55–72.
60. Ayton, S., et al. Biometals and their therapeutic implications in Alzheimer's disease. Neurotherapeutics 12 (2015), 109–120.
61. Pretorius, E., et al. A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy. Toxicol. Mech. Methods 23 (2013), 352–359.
62. Rajendran, R., et al. A novel approach to the identification and quantitative elemental analysis of amyloid deposits – insights into the pathology of Alzheimer's disease. Biochem. Biophys. Res. Commun. 382 (2009), 91–95.
63. Prousek, J., Fenton chemistry in biology and medicine. Pure Appl. Chem. 79 (2007), 2325–2338.
64. La Penna, G., et al. Identifying, by first-principles simulations, Cu[amyloid-β] species making Fenton-type reactions in Alzheimer's disease. J. Phys. Chem. B 117 (2013), 16455–16467.
65. Hatanaka, H., et al. Differences in peripheral oxidative stress markers in Alzheimer's disease, vascular dementia and mixed dementia patients. Geriatr. Gerontol. Int. 15:Suppl 1 (2015), 53–58.
66. Butterfield, D.A., Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease. Free Radic. Res. 45 (2011), 59–72.
67. Gertsik, N., et al. Complex regulation of γ-secretase: from obligatory to modulatory subunits. Front. Aging Neurosci., 7, 2015, 342.
68. Gwon, A.R., et al. Oxidative lipid modification of nicastrin enhances amyloidogenic γ-secretase activity in Alzheimer's disease. Aging Cell 11 (2012), 559–568.
69. Dwyer, B.E., et al. Homocysteine and Alzheimer's disease: a modifiable risk?. Free Radic. Biol. Med. 36 (2004), 1471–1475.
70. Cummings, J., et al. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res. Ther., 8, 2016, 39.
71. Godyń, J., et al. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol. Rep. 68 (2016), 127–138.
72. Galimberti, D., Scarpini, E., Old and new acetylcholinesterase inhibitors for Alzheimer's disease. Expert Opin. Investig. Drugs 25 (2016), 1181–1187.
73. Brinkman, S.D., Gershon, S., Measurement of cholinergic drug effects on memory in Alzheimer's disease. Neurobiol. Aging 4 (1983), 139–145.
74. Fusek, J., et al. Anticholinesterase effects of 9-amino-7-methoxy-1,2,3,4-tetrahydroacridine. Act. Nerv. Super. 28 (1986), 327–328.
75. Minarini, A., et al. Multifunctional tacrine derivatives in Alzheimer's disease. Curr. Top. Med. Chem. 13 (2013), 1771–1786.
76. Rodríguez-Franco, M.I., Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 49 (2006), 459–462.
77. Sun, Q., et al. Syntheses of coumarin–tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase. Bioorg. Med. Chem. 22 (2014), 4784–4791.
78. Nepovimova, E., et al. Tacrine–trolox hybrids: a novel class of centrally active, nonhepatotoxic multi-target-directed ligands exerting anticholinesterase and antioxidant activities with low in vivo toxicity. J. Med. Chem. 58 (2015), 8985–9003.
79. Hamulakova, S., et al. Targeting copper(II)-induced oxidative stress and the acetylcholinesterase system in Alzheimer's disease using multifunctional tacrine-coumarin hybrid molecules. J. Inorg. Biochem. 161 (2016), 52–62.
80. Richardson, D.R., Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. N. Y. Acad. Sci. 1012 (2004), 326–341.
81. Sharpe, P.C., Richardson, D.R., Synthetic and natural products as iron chelators. Curr. Top. Med. Chem. 11 (2011), 591–607.
82. Richardson, D.R., et al. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J. Med. Chem. 52 (2009), 1459–1470.
83. Whitnall, M., Richardson, D.R., Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin. Pediatr. Neurol. 13 (2006), 186–197.
84. 2+ complexes in Alzheimer's disease. Aging Cell 5 (2006), 69–79.
85. Adlard, P.A., et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59 (2008), 43–55.
86. Crouch, P.J., et al. The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity. J. Neurochem. 119 (2011), 220–230.
87. White, A.R., et al. Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281 (2006), 17670–17680.
88. Donnelly, P.S., et al. Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-β peptide. J. Biol. Chem. 283 (2008), 4568–4577.
89. Kaden, D., et al. Disturbed copper bioavailability in Alzheimer's disease. Int. J. Alzheimers. Dis., 2011, 2011, 345614.
90. Kenche, V.B., Barnham, K.J., Alzheimer's disease & metals: therapeutic opportunities. Br. J. Pharmacol. 163 (2011), 211–219.
91. Schlief, M.L., Gitlin, J.D., Copper homeostasis in the CNS. Mol. Neurobiol. 33 (2006), 81–90.
92. Zheng, H., et al. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. J. Med. Chem. 52 (2009), 4095–4098.
93. Amit, T., et al. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J. 22 (2008), 1296–1305.
94. Arlt, S., et al. Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease. Neurochem. Res. 37 (2012), 2706–2714.
95. Baptista, F.I., et al. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS Chem. Neurosci. 5 (2014), 83–92.
96. Costa, L.G., et al. Mechanisms of neuroprotection by quercetin: counteracting oxidative stress and more. Oxid. Med. Cell. Longev., 2016, 2016, 2986796.